ScoreWhy is Samrat Pharmachem Ltd ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
2
Flat results in Sep 25
- OPERATING CF(Y) Lowest at Rs -10.09 Cr
- PBDIT(Q) Lowest at Rs -0.36 cr.
- OPERATING PROFIT TO NET SALES (Q) Lowest at -0.46%
3
With ROE of 2.2, it has a Very Expensive valuation with a 1 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -32.62%, its profits have fallen by -75.9%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -32.62% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Samrat Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Samrat Pharma
-32.62%
-0.73
44.96%
Sensex
8.52%
0.74
11.46%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.26%
EBIT Growth (5y)
-9.88%
EBIT to Interest (avg)
12.29
Debt to EBITDA (avg)
1.80
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
3.88
Tax Ratio
48.17%
Dividend Payout Ratio
4.34%
Pledged Shares
0
Institutional Holding
3.24%
ROCE (avg)
21.43%
ROE (avg)
16.23%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
47
Industry P/E
33
Price to Book Value
1.03
EV to EBIT
19.19
EV to EBITDA
15.97
EV to Capital Employed
1.04
EV to Sales
0.22
PEG Ratio
NA
Dividend Yield
0.42%
ROCE (Latest)
5.41%
ROE (Latest)
2.21%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-8What is not working for the Company
OPERATING PROFIT TO NET SALES(Q)
Lowest at -1.02%
PBT LESS OI(Q)
Lowest at Rs -0.97 cr.
NET SALES(Q)
Lowest at Rs 63.43 cr
PBDIT(Q)
Lowest at Rs -0.65 cr.
Loading Valuation Snapshot...
Here's what is not working for Samrat Pharma
Net Sales - Quarterly
At Rs 63.43 cr has Fallen at -12.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 72.35 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Operating Profit Margin - Quarterly
Lowest at -1.02% and Fallen
each quarter in the last five quartersMOJO Watch
Company's efficiency has deteriorated
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs -0.97 cr. and Fallen
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Net Sales - Quarterly
Lowest at Rs 63.43 cr
in the last five quartersMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Lowest at Rs -0.65 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
